Improve standards of care for MND patients Provide symptomatic relief and and make assistive technologies developed at SITraN widely available to MND patients to improve their quality of life and life expectancy through exemplary care at all disease stages.
Diagnose neurodegenerative diseases earlier Identify biomarkers and develop better tools and neuroimaging techniques to diagnose MND, Parkinson's and Alzheimer's disease earlier in order that existing as well as new therapies have a better chance of working and can be evaluated on a more rapid time scale.
Develop new therapeutic strategies Establish environmental risk factors and investigate mechanisms of motor neuron injury in new genetic subtypes and sporadic cases to identify new targets for neuroprotective therapy development and prevention.
Develop and optimise disease models Develop sophisticated new in vitro and in vivo models for genetic and sporadic variants of neurodegenerative disorders that closely mirror human disease to screen and develop drugs suitable for these disease subtypes.
Take promising drug screening candidates through to clinical trials Build on our extensive drug screening programme and bring some of our preliminary therapeutic agents, including gene therapy products, into clinical trials for patients with MND and related conditions; develop new gene therapy approaches for genetic disease variants.
Use genomics to develop tailored treatments Establish a Centre for Genome Translation at SITraN to use genomics to identify the actual causal basis of diseases and so develop tailored treatments for patients according to the underlying causes of the disease.
Accelerate the pace of therapy development Train our scientists in cutting edge technologies and provide state-of-the-art equipment to accelerate the pace of discoveries and therapy development.
Strengthen crucial research programmes Complete senior appointments in Stem Cell Neurobiology and Drug Discovery to strengthen our research in these areas and accelerate the development of treatments.
Join forces to achieve our common goal faster together Continue to collaborate with researchers and charities worldwide to avoid duplication, make the best use of resources and achieve our common goal faster together – to improve significantly the lives of families affected by MND and related conditions.
Secure the future stability and growth of our research at SITraN by obtaining core “centre” funding and committed long-term sponsorship.